Form 4 Filing for Doyle Mittie

On April 1, 2026, Doyle Mittie, Chief Medical Officer of Avalo Therapeutics, Inc., executed a series of transactions involving the company's Common Stock. Mittie acquired 679 shares at $8.04 per share and disposed of 679 shares at $16.00 per share, both under a Rule 10b5-1 trading plan. Following these transactions, Mittie holds 3622 shares. Additionally, Mittie exercised a stock option to acquire 679 shares, with the option vesting details noted in footnote F2. The option has a strike price of $8.04 and an exercise date referenced in footnote F2, with an expiration date of January 28, 2035. Post-exercise, Mittie holds 148,329 shares underlying the option.